PortfoliosLab logoPortfoliosLab logo
MRNA vs. SXRM.DE
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

MRNA vs. SXRM.DE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Moderna, Inc. (MRNA) and iShares USD Treasury Bond 7-10yr UCITS ETF (Acc) (SXRM.DE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, MRNA achieves a 69.24% return, which is significantly higher than SXRM.DE's -0.59% return.


MRNA

1D
0.54%
1M
-0.24%
YTD
69.24%
6M
69.42%
1Y
87.14%
3Y*
-26.94%
5Y*
-25.59%
10Y*

SXRM.DE

1D
0.38%
1M
0.09%
YTD
-0.59%
6M
0.05%
1Y
4.19%
3Y*
2.95%
5Y*
-1.07%
10Y*
0.67%
*Multi-year figures are annualized to reflect compound growth (CAGR)

MRNA vs. SXRM.DE - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
MRNA
Moderna, Inc.
69.24%-29.08%-58.19%-44.63%-29.28%143.11%434.10%28.09%-30.59%
SXRM.DE
iShares USD Treasury Bond 7-10yr UCITS ETF (Acc)
-0.59%8.56%-0.51%3.57%-14.86%-3.03%9.73%9.02%0.85%

Correlation

The correlation between MRNA and SXRM.DE is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.19

Correlation (3Y)
Calculated over the trailing 3-year period

0.10

Correlation (5Y)
Calculated over the trailing 5-year period

0.10

Correlation (All Time)
Calculated using the full available price history since Dec 7, 2018

0.08

The correlation between MRNA and SXRM.DE shifts across timeframes, from 0.08 (all time) to 0.19 (1 year), reflecting how their relationship changes across market environments.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MRNA vs. SXRM.DE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MRNA
MRNA Risk / Return Rank: 7878
Overall Rank
MRNA Sharpe Ratio Rank: 8080
Sharpe Ratio Rank
MRNA Sortino Ratio Rank: 7979
Sortino Ratio Rank
MRNA Omega Ratio Rank: 7575
Omega Ratio Rank
MRNA Calmar Ratio Rank: 7979
Calmar Ratio Rank
MRNA Martin Ratio Rank: 7676
Martin Ratio Rank

SXRM.DE
SXRM.DE Risk / Return Rank: 2424
Overall Rank
SXRM.DE Sharpe Ratio Rank: 2626
Sharpe Ratio Rank
SXRM.DE Sortino Ratio Rank: 2525
Sortino Ratio Rank
SXRM.DE Omega Ratio Rank: 2323
Omega Ratio Rank
SXRM.DE Calmar Ratio Rank: 2323
Calmar Ratio Rank
SXRM.DE Martin Ratio Rank: 2424
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MRNA vs. SXRM.DE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Moderna, Inc. (MRNA) and iShares USD Treasury Bond 7-10yr UCITS ETF (Acc) (SXRM.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


MRNASXRM.DEDifference
Sharpe ratioReturn per unit of total volatility

+0.46

Sortino ratioReturn per unit of downside risk

+0.90

Omega ratioGain probability vs. loss probability

1.24

1.14

+0.10

Calmar ratioReturn relative to maximum drawdown

2.34

0.93

+1.41

Martin ratioReturn relative to average drawdown

4.59

2.74

+1.85

MRNA vs. SXRM.DE - Sharpe Ratio Comparison

The current MRNA Sharpe Ratio is 1.28, which is higher than the SXRM.DE Sharpe Ratio of 0.82. The chart below compares the historical Sharpe Ratios of MRNA and SXRM.DE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

MRNA vs. SXRM.DE - Drawdown Comparison

The maximum MRNA drawdown since its inception was -95.38%, which is greater than SXRM.DE's maximum drawdown of -23.31%. Use the drawdown chart below to compare losses from any high point for MRNA and SXRM.DE.


Loading charts...

Drawdown Indicators


MRNASXRM.DEDifference

Max Drawdown

Largest peak-to-trough decline

-95.38%

-23.31%

-72.07%

Max Drawdown (1Y)

Largest decline over 1 year

-35.51%

-4.02%

-31.49%

Max Drawdown (3Y)

Largest decline over 3 years

-86.58%

-7.24%

-79.34%

Max Drawdown (5Y)

Largest decline over 5 years

-95.38%

-20.90%

-74.48%

Max Drawdown (10Y)

Largest decline over 10 years

-23.31%

Current Drawdown

Current decline from peak

-89.70%

-10.34%

-79.36%

Average Drawdown

Average peak-to-trough decline

-57.06%

-6.45%

-50.61%

Ulcer Index

Depth and duration of drawdowns from previous peaks

18.06%

1.37%

+16.69%

Volatility

MRNA vs. SXRM.DE - Volatility Comparison

Moderna, Inc. (MRNA) has a higher volatility of 17.56% compared to iShares USD Treasury Bond 7-10yr UCITS ETF (Acc) (SXRM.DE) at 1.86%. This indicates that MRNA's price experiences larger fluctuations and is considered to be riskier than SXRM.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


MRNASXRM.DEDifference

Volatility (1M)

Calculated over the trailing 1-month period

17.56%

1.86%

+15.70%

Volatility (6M)

Calculated over the trailing 6-month period

48.82%

3.41%

+45.41%

Volatility (1Y)

Calculated over the trailing 1-year period

64.75%

4.60%

+60.15%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

66.49%

7.38%

+59.11%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

72.15%

6.30%

+65.85%

Dividends

MRNA vs. SXRM.DE - Dividend Comparison

Neither MRNA nor SXRM.DE has paid dividends to shareholders.


Tickers have no history of dividend payments

Frequently Asked Questions


MRNA and SXRM.DE have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for MRNA and SXRM.DE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer